Skip to main content

Latest oncology news

25-04-2019 | Oncology | News | Article

LATITUDE final analysis confirms abiraterone benefit for mCSPC

Adding abiraterone acetate plus prednisone to androgen deprivation therapy continues to provide an overall survival advantage in the first-line treatment of men with high-risk metastatic castration-sensitive prostate cancer, report the LATITUDE investigators.

24-04-2019 | Oncology | News | Article

Bevacizumab–erlotinib improves PFS in advanced EGFR mutation-positive NSCLC

Combining erlotinib with bevacizumab is associated with a significant prolongation of progression-free survival in chemotherapy-naïve patients with advanced nonsquamous non-small-cell lung cancer harboring an activating EGFR mutation, indicates a phase III trial.

23-04-2019 | Oncology | News | Article

SABR may improve survival in oligometastatic cancer

The phase II SABR-COMET study has indicated that stereotactic ablative radiotherapy prolongs overall and progression-free survival versus palliative treatment in patients with up to five oligometastases.

18-04-2019 | Oncology | News | Article

ABCP benefits shown in key NSCLC subgroups

Patients with nonsquamous non-small-cell lung cancer who have sensitizing EGFR mutations or liver metastases may benefit from the addition of atezolizumab to bevacizumab and chemotherapy, IMpower150 trial data show.

18-04-2019 | Diabetes | News | Article

Study bolsters evidence for 5 alpha-reductase inhibitor link to type 2 diabetes

Men with benign prostatic hyperplasia undergoing long-term treatment with 5α-reductase inhibitors are significantly more likely to develop type 2 diabetes than those receiving the α-blocker tamsulosin, population-based study data show.

18-04-2019 | Oncology | News | Article

68Ga-PSMA-11 PET shows ‘high accuracy’ for localizing recurrent prostate cancer

Positron emission tomography using 68gallium-labeled ligands of the prostate-specific membrane antigen is accurate, reproducible, and safe in localizing biochemically recurrent prostate cancer, according to the results of a prospective trial.

17-04-2019 | Oncology | News | Article

Conflicting data reported on immunotherapy benefit for older NSCLC patients

The overall survival benefit of immunotherapy in elderly patients with advanced non-small-cell lung cancer is unclear according to two studies with contradictory results presented at the European Lung Cancer Congress 2019 in Geneva, Switzerland.

16-04-2019 | Oncology | News | Article

CheckMate 451: Maintenance immunotherapy fails to improve SCLC survival

Maintenance treatment with nivolumab, either given alone or alongside ipilimumab, does not prolong the overall survival of patients with extensive-stage small-cell lung cancer, the CheckMate 451 investigators have found.

15-04-2019 | Oncology | News | Article

Guidance needed to encourage cancer patients, physicians to discuss CAM use

A third of cancer patients and survivors use complementary and alternative medicine, but they do not always disclose its use to their physicians, findings indicate.

12-04-2019 | Oncology | News | Article

ALK resistance mutations predict lorlatinib efficacy in NSCLC patients progressing on ALK–TKIs

Lorlatinib is more efficacious against non-small-cell lung cancer with versus without ALK resistance mutations in patients with disease progression after at least one second-generation ALK–tyrosine kinase inhibitor, suggests research.

12-04-2019 | Oncology | News | Article

KEYNOTE-042 leads to first-line pembrolizumab approval for stage III NSCLC

Read more on this FDA announcement here

12-04-2019 | Oncology | News | Article

Lung cancer screening benefits increase over time

The Multicentric Italian Lung Detection study findings indicate that extending lung cancer screening beyond 5 years boosts the survival benefits associated with early disease detection.

11-04-2019 | Oncology | News | Article

Prostate cancer incidence, mortality has decreased or stabilized in many countries

Research reported at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA, shows that the incidence of prostate cancer and associated mortality has generally declined or remained steady in most of the countries with available data.

10-04-2019 | Oncology | News | Article

Clinical value of genotyping cfDNA demonstrated in advanced NSCLC setting

The NILE study has shown the noninferiority of cell-free DNA analysis, so-called liquid biopsy, to the standard of care for identifying targetable biomarkers in individuals with treatment-naïve metastatic non-small-cell lung cancer.

09-04-2019 | Oncology | News | Article

Durvalumab maintenance for unresectable NSCLC approved for UK patients

Read more on this decision here

08-04-2019 | Oncology | News | Article

SPARTAN: Apalutamide benefit seen for luminal, basal nonmetastatic CRPC

Supplementing androgen deprivation therapy with apalutamide improves metastasis-free survival in patients with the luminal and basal subtypes of nonmetastatic castration-resistant prostate cancer, indicates an analysis of the randomized SPARTAN trial.

08-04-2019 | Oncology | News | Article

FDA approves point-of-care PSA test

Click through to read the details

05-04-2019 | Oncology | News | Article

Entrectinib has antitumor efficacy in NTRK fusion-positive tumors

The multikinase inhibitor entrectinib elicits systemic and intracranial responses in patients with locally advanced or metastatic solid tumors harboring NTRK fusions, including those with non-small-cell lung cancer, suggests a pooled analysis of three early-phase clinical trials.

04-04-2019 | Oncology | News | Article

LOXO-195 could be an option for tumors resistant to first-generation TRK inhibitors

Early findings point to the antitumor efficacy of the next-generation TRK inhibitor LOXO-195 in patients with NTRK fusion-positive cancers and NTRK resistance mutations acquired during treatment with first-generation agents.

03-04-2019 | Oncology | Highlight | Article

Osimertinib combinations promising for NSCLC patients with acquired resistance to EGFR–TKIs

Data from the phase Ib TATTON trial suggest that patients with EGFR-mutated non-small-cell lung cancer who have progressed on prior EGFR–tyrosine kinase inhibitor therapy could benefit from adding either the MET inhibitor savolitinib or the MEK inhibitor selumetinib to osimertinib.

image credits